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Autism spectrum disorders (ASDs) are genetically and clinically heterogeneous and lack
effective medications to treat their core symptoms. Studies of syndromic ASDs caused
by single gene mutations have provided insights into the pathophysiology of autism.
Fragile X and Rett syndromes belong to the syndromic ASDs in which preclinical studies
have identified rational targets for drug therapies focused on correcting underlying neural
dysfunction. These preclinical discoveries are increasingly translating into exciting human
clinical trials. Since there are significant molecular and neurobiological overlaps among
ASDs, targeted treatments developed for fragile X and Rett syndromes may be helpful for
autism of different etiologies. Here, we review the targeted pharmacological treatment of
fragile X and Rett syndromes and discuss related issues in both preclinical studies and
clinical trials of potential therapies for the diseases.
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INTRODUCTION
Autism spectrum disorders (ASDs) encompass a group
of neurodevelopmental disorders which are of different
etiologies and characterized by impairments in socialization
and communication, abnormalities in language development,
restricted interests, and repetitive and stereotyped behaviors
(Mefford et al., 2012; Zoghbi and Bear, 2012; Murdoch and
State, 2013; Anagnostou et al., 2014b; Lai et al., 2014). These
disorders are estimated to affect approximately 1% of the
population. The genetic causes of ASDs show a high degree
of heterogeneity, with hundreds of ASD-associated genes
now identified (Mefford et al., 2012; Huguet et al., 2013;
Murdoch and State, 2013; Lai et al., 2014; Ronemus et al.,
2014). However, recent studies suggest that these ASD genes
may functionally converge into a relatively smaller subset of
cellular and biochemical pathways affecting distinct neuronal
functions (Auerbach et al., 2011; Zoghbi and Bear, 2012; Ebert
and Greenberg, 2013; Doll and Broadie, 2014; Krumm et al.,
2014). In a subset of ASDs, such as the syndromic ASD fragile
X syndrome, Rett syndrome (RTT) and tuberous sclerosis,
mutations of genes have been found to be related to synaptic
function, suggesting that abnormal neuronal homeostasis is
a risk factor for ASD (Auerbach et al., 2011; Santoro et al.,
2012; Zoghbi and Bear, 2012; Ebert and Greenberg, 2013;
Banerjee et al., 2014). This subset of ASDs belong to a larger
group of neurological conditions called “synaptopathies”,
which refer to disorders with altered synaptic function and/or
morphology as primary neuropathology (Auerbach et al., 2011;
Zoghbi and Bear, 2012; Krumm et al., 2014). The functional
convergence on particular signaling pathways and the shared
synaptopathology of ASDs have raised the hope that similar
therapeutic strategies may be effective for different forms
of ASDs which are related, but genetically distinct (Zoghbi
and Bear, 2012; Delorme et al., 2013; Wang and Doering,
2013).
Fragile X and Rett syndromes are two of the most widely
and intensively studied monogenetic ASDs (Santoro et al., 2012;
Zoghbi and Bear, 2012; Castro et al., 2013; Chapleau et al., 2013a;
Banerjee et al., 2014). Numerous studies have investigated the
possibility of treating fragile X and Rett syndromes in their relative
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animal models. Strategies to alleviate abnormal phenotypes
include genetic manipulation, cellular therapy, pharmacological
intervention and environmental stimulation (Wang and Doering,
2012; Zoghbi and Bear, 2012; Castro et al., 2013; Chapleau et al.,
2013a; Delorme et al., 2013; Ebert and Greenberg, 2013). Most
encouraging, some of these fundamental studies have led to the
development of drugs that are in clinical trials.
In this review, we summarize the potential therapeutic targets
and relative pharmacological interventions in fragile X and Rett
syndromes. The challenges in preclinical studies and clinical trials,
and the implications of these targeted pharmacological treatments
for other ASDs and related neurodevelopmental disorders are also
discussed.
TARGETED PHARMACOTHERAPY FOR FRAGILE X SYNDROME
Fragile X syndrome is one of the most common genetic
causes of intellectual disability and autism. It is mostly caused
by the mutation of the trinucleotide CGG expansion in the
5′-untranslated region of the fragile X mental retardation
(FMR1) gene, which eventually leads to the absence of its
protein product, fragile X mental retardation protein (FMRP)
(Garber et al., 2008; Bhakar et al., 2012; Santoro et al., 2012;
Hagerman et al., 2014). FMRP is ubiquitous with the most
abundance in the central nervous system (Santoro et al., 2012;
Wang et al., 2012a; Sidorov et al., 2013) and exists in both
neurons and glial cells (Wang et al., 2004; Pacey and Doering,
2007).
FMRP, a RNA binding protein, binds its mRNA targets and
regulates the transport and translation of those mRNAs (Bear
et al., 2004; Penagarikano et al., 2007; Bhakar et al., 2012;
Santoro et al., 2012; Wang et al., 2012a; Sidorov et al., 2013;
Abekhoukh and Bardoni, 2014). The mRNA targets of FMRP
encode pre- and post-synaptic proteins and some of these proteins
are implicated in other ASDs, suggesting a molecular overlap
between fragile X syndrome and other neurodevelopmental
disorders (Bhakar et al., 2012; Wang et al., 2012a; Sidorov
et al., 2013). FMRP normally acts as a translational repressor,
especially at synapses. Its absence has profound consequences
on neural development and synaptic plasticity. Alterations in
synaptic structure and function are believed to underlie the
fragile X symptoms. Dysregulated protein synthesis is central
to fragile X synaptopathy (Bear et al., 2004; Penagarikano
et al., 2007; Bassell and Warren, 2008; Wang et al., 2010a;
Bhakar et al., 2012; Santoro et al., 2012; Sidorov et al.,
2013).
Over the past two decades, efforts have been made to elucidate
the molecular and cellular events that give rise to synaptic
dysfunction in fragile X syndrome. Studies in animal models
have revealed defects in multiple neurotransmitter systems and
relative signaling pathways/molecules that are responsible for
fragile X synaptopathy (Wang et al., 2010b; Bhakar et al.,
2012; Gross et al., 2012; Santoro et al., 2012; Zoghbi and
Bear, 2012; Delorme et al., 2013; Ebert and Greenberg, 2013).
Advances in neurobiology of fragile X syndrome have led
to the development of therapeutic agents that target the
underlying mechanisms of the disease (Summarized in Figure 1;
Tables 1, 2).
TARGETING NEUROTRANSMITTER/NEUROMODULATOR SYSTEMS
Metabotropic glutamate receptors
Metabotropic glutamate receptors (mGluRs) play important
roles in synaptic plasticity, learning and memory (Bortolotto
et al., 1999; Bear et al., 2004; Wang et al., 2008a; Wang
and Zhuo, 2012; Mukherjee and Manahan-Vaughan, 2013).
Activation of group 1 mGluRs (mGluR1s and mGluR5s) leads
to local translation of pre-existing mRNAs and triggers long-
term depression (LTD) (Weiler and Greenough, 1993; Bortolotto
et al., 1999; Raymond et al., 2000; Penagarikano et al., 2007;
Ronesi and Huber, 2008a; Upreti et al., 2013). FMRP is one
of these newly synthesized proteins and serves as a repressor
of the translation of other synaptic mRNAs that encode
LTD proteins such as activity-regulated cytoskeleton-associated
protein (Arc), microtubule associated protein (MAP) 1B and
Striatal-enriched protein tyrosine phosphatase (STEP), which
mediate a-amino-3-hydroxyl-4-isoxazole propionic acid receptor
(AMPAR) internalization and LTD stabilization (Bhakar et al.,
2012; Santoro et al., 2012; Wang et al., 2012a; Darnell and
Klann, 2013; Sidorov et al., 2013). In fragile X conditions, protein
synthesis is elevated and mGluR-LTD in the hippocampus is
exaggerated in the absence of FMRP; the enhanced mGluR-
LTD is no longer protein synthesis dependent as a result
of increased basal protein synthesis. The mGluR theory of
fragile X syndrome thus postulates that the core symptoms of
the disease result from exaggerated group 1 mGluR mediated
signaling including mGluR-LTD (Bear et al., 2004; Garber et al.,
2008; Bhakar et al., 2012; Santoro et al., 2012; Sidorov et al.,
2013).
The mGluR theory and its therapeutic significance have
been validated in both genetic and pharmacological rescue
studies (Dölen and Bear, 2008; Hays et al., 2011; Thomas
et al., 2011; Gandhi et al., 2014; Michalon et al., 2014;
Pop et al., 2014). In Fmr1 knockout mice, the mGluR5
antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP)
stabilized hippocampal protein synthesis, increased the density
or rescued the morphology of hippocampal dendritic spines,
corrected altered brain network function, reduced audiogenic
seizures and repetitive and/or perseverative behaviors (marble
burying), rescued the deficits in prepulse inhibition of startle
response, and improved the maze and motor learning (Yan
et al., 2005; de Vrij et al., 2008; Hays et al., 2011; Thomas
et al., 2012; Gandhi et al., 2014). Other mGluR5 antagonists
tested in fragile X animal models include CTEC, fenobam
and AFQ056. Acute treatment with CTEC corrected the
elevated hippocampal LTD, protein synthesis, and audiogenic
seizures; chronic treatment rescued cognitive deficits, auditory
hypersensitivity, aberrant dendritic spine density, overactive
extracellular signal regulated kinase (ERK) and mammalian
target of rapamycin (mTOR) signaling, and partially corrected
macroorchidism in adult fragile X mice (Michalon et al., 2012).
Chronic CTEP treatment also corrected learning deficit in the
inhibitory avoidance and extinction test, and partially normalized
altered local brain activity in these animals (Michalon et al.,
2014). Fenobam reversed some synaptic alterations in the
cortex (Wang et al., 2014) and corrected deficits in associative
motor learning and avoidance behaviors in fragile X mice
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FIGURE 1 | Signaling molecules and pathways in the neurobiology of
fragile X syndrome. In signaling pathways, arrows indicate positive (green)
or inhibitory (red) consequence on downstream components, but they do not
necessarily represent direct interactions. Potential therapeutic targets which
have been validated by genetic or pharmacological manipulation are indicated
by red stars or highlighted by red circles. Abbreviations: 2-AG,
2-arachidonoyl-sn-glycerol; 4E-BP2, eIF4E-binding protein 2; 5-HT, serotonin;
5-HTR, serotonin receptors; 5-HTT, serotonin transporters; Akt (PKB), protein
kinase B; AMPAR, α-amino-3-hydroxyl-4-isoxazole propionic acid receptors;
APP, amyloid precursor protein; CB1(2)R, cannabinoid receptor 1(2); EphB-R,
EphB receptors; ERK, extracellular signal related kinase; FMRP, fragile X
mental retardation protein; GABA, gamma aminobutyric acid; GABAA(B)R,
GABAA(B) receptors; GSK3, glycogen synthase kinase-3; JNK, c-Jun
N-terminal kinase; M1/4R, muscarinic acetylcholine receptor 1/4; MEK,
mitogen-activated protein kinase/ERK kinase; MGL, monoacylglycerol lipase;
mGluR, metabotropic glutamate receptor; MMP9, matrix metalloproteinase
9; MSK, mitogen and stress-activated protein kinase; mTOR, mammalian
target of rapamycin; NF1, neurofibromatosis 1; NMDAR, N-methyl-d-aspartate
receptors; OXTR, oxytocin receptor; PAK, p21-activated kinase; PI3K,
phosphatidylinositol 3-kinase; PKC, protein kinase C; PP2A, protein
phosphatase 2A; PTEN, Phosphatase and tensin homolog; Raptor,
regulatory-associated protein of mTOR; RSK, p90 ribosomal S6 kinase; S6K1,
p70 ribosomal kinase 1; STEP, striatal-enriched protein tyrosine phosphatase;
TSC1/2, tuberous sclerosis complex 1/2.
(Vinueza Veloz et al., 2012). AFQ056 was found to be able
to correct aberrant hippocampal dendritic spine morphology
(Levenga et al., 2011; Pop et al., 2014), and rescue deficits in
prepulse inhibition of acoustic startle response and abnormal
social behaviors (Levenga et al., 2011; Gantois et al., 2013) in
Fmr1 knockout mice. Treatment with mGluR1 antagonists
(JNJ16259685 or LY367385) decreased repetitive and/or
perseverative behaviors (Thomas et al., 2012), and rescued
dysregulated synaptic protein synthesis in fragile X mice (Gross
et al., 2010; Guo et al., 2012). These preclinical studies have
been paving the way for treatments with mGluR antagonists in
humans.
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Table 1 | Therapeutic targets and relative drugs in preclinical studies of fragile X syndrome.
Targets Drugs Action
Neurotransmitter receptors or transporters mGluR5 MPEP, CTEC, fenobam, AFQ056 Antagonists
mGluR1 JNJ16259685, LY367385 Antagonists
GABAA receptor THIP, ganaxolone Agonists
GABAB receptor Baclofen, arbaclofen (STX209) Agonists
5-HT7 receptor 8-OH-DPAT Agonist
5-HT2B receptor BW723C86 Agonist
5-HT2A receptor αMe-5HT, MDL11939 Antagonists
5-HTT Fluoxetine 5-HT reuptake inhibitor
Dopamine D1 receptor SKF81297 Agonist
CB1R Rimonabant Antagonist
CB2R AM630 Antagonist
MGL JZL184 Inhibitor
M1R Dicyclomine Antagonist
M4R Tropicamide Antagonist
NMDAR Memantine Antagonist
Protein kinases or other enzymes ERK SL327, U0126, lovastatin Inhibitors
JNK SP600125 Inhibitor
PI3K LY294002, TGX-221 Inhibitors
PTEN BpV Inhibitor
mTOR Temsirolimus, rapamycin, LY294002, TGX221 Inhibitors
GSK3 Lithium, SB216763 TDZD-8, YP0.7 Inhibitors
MMP9 Minocycline Inhibitor
PAK FRAX486 Inhibitor
Ion channels Kv4 channel HpTx2 Blocker
BK channel BMS-204352 Opener
Table 2 | Drugs in clinical trials of fragile X syndrome.
Drugs Action Study designs Publications
Fenobam mGluR5 antagonist Open label pilot study; single dose Berry-Kravis et al. (2009)
AFQ056 mGluR5 antagonist Randomized, double-blind, two treatment,
two-period crossover study
Jacquemont et al. (2011)
RO4917523 mGluR5 antagonist Randomized, double-blinded,
placebo-controlled study
Discontinued due to negative
results†
Ganaxolone GABAA receptor agonist Double-blind, controlled trial www.clinicaltrials.gov
Acamprosate GABA receptor agonist Open-label, uncontrolled trial Erickson et al. (2010, 2013)
Arbaclofen (STX209) GABAB receptor agonist Randomized, double-blind,
placebo-controlled study
Berry-Kravis et al. (2012)
Oxytocin OXTR agonist Double-blind, placebo-controlled study Hall et al. (2012)
CX516 AMPAR positive modulator Randomized, double-blind,
placebo-controlled study
Berry-Kravis et al. (2006)
Memantine NMDAR antagonist Open-label study Erickson et al. (2009)
Lovastatin ERK inhibitor Open-label study Çaku et al. (2014)
Lithium GSK3 inhibitor Open-label study Berry-Kravis et al. (2008)
Minocycline MMP9 inhibitor Open-label add-on pilot trial Paribello et al. (2010)
Randomized, double-blind,
placebo-controlled and crossover trial
Leigh et al. (2013)
†www.fragilex.org
Fenobam, the first mGluR antagonist used in patients, showed
beneficial effects, such as reduced anxiety and hyperarousal,
improved prepulse inhibition of startle, and better accuracy
on a continuous performance task, in adults with fragile X
syndrome (Berry-Kravis et al., 2009). The pharmacokinetics
and side effects of fenobam are currently tested in adult
healthy volunteers.1 AFQ056 also showed improvements in
inappropriate speech, stereotypic behavior, and hyperactivity
1www.clinicaltrials.gov
and efficacy in adult patients with fully methylated FMR1
(Jacquemont et al., 2011). However, the mGluR5 negative
allosteric modulator RG7090 (RO4917523) in fragile X was
recently discontinued by Roche due to negative phase II clinical
study results from fragile X patients.2 More drugs targeting
mGluRs with higher efficacy and better safety need to be
developed in the future (Berry-Kravis, 2014; Hagerman et al.,
2014).
2www.fragilex.org
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GABAergic receptors
The γ-aminobutyric acid (GABA) is the main inhibitory
neurotransmitter in brain and signals through GABAA and
GABAB receptors (Ben-Ari et al., 2012; Gassmann and Bettler,
2012; Sigel and Steinmann, 2012). The deficiencies in GABA
receptor expression and GABA receptor-mediated inhibition
have been demonstrated in fragile X animal models, linking
GABA receptors to fragile X phenotypes and leading to
the hypothesis that fragile X syndrome may result from an
imbalance between excitation and inhibition, and increasing
inhibition may ameliorate some fragile X pathophysiologies,
including dysregulated protein synthesis (D’Hulst et al., 2006,
2009; Chang et al., 2008; Pacey et al., 2009; Olmos-Serrano
et al., 2010; Paluszkiewicz et al., 2011; He et al., 2014). The
potential of GABA receptors as a therapeutic target for fragile
X syndrome has been validated in animal models. Treatment
with a selective GABAA receptor agonist THIP (gaboxadol)
corrected neuronal hyperexcitability in the amygdala (Olmos-
Serrano et al., 2010), and attenuated hyperactivity and deficits
in prepulse inhibition of the acoustic startle response of
fragile X mice (Olmos-Serrano et al., 2011). Treatment with
ganaxolone, a positive allosteric modulator of GABAA receptors,
could prevent audiogenic seizures in Fmr1 knockout mice
(Heulens et al., 2012). The GABAB receptor agonist baclofen
reduced locomotor activity and hyperactivity (Zupan and
Toth, 2008), and ameliorated audiogenic seizure susceptibility
of Fmr1 knockout mice (Pacey et al., 2009, 2011). Notably,
arbaclofen (STX209), the R-isomer of baclofen, was also able to
attenuate audiogenic seizures in fragile X mice (Henderson et al.,
2012). In addition, arbaclofen corrected dysregulated protein
synthesis in the hippocampus, restored the elevated AMPA
receptor internalization and the increased spine density, and thus
corrected synaptic abnormalities which are central to fragile X
pathophysiologies, suggesting that arbaclofen could be potentially
used to treat the core symptoms of fragile X patients (Henderson
et al., 2012).
A large clinical trial with ganaxolone is currently ongoing
in children and adolescents with fragile X syndrome between 6
to 17 years of age (Wijetunge et al., 2013; Berry-Kravis, 2014;
Hagerman et al., 2014).3 A controlled trial of arbaclofen in 63
fragile X patients between 6 to 40 years of age has revealed
significant beneficial treatment effects, such as improvements
in socialization and social avoidance scores, particularly in
those with more severe social impairments, suggesting that
GABAB receptor agonists have potential to improve social
function and behaviors in fragile X patients (Berry-Kravis
et al., 2012). However, this clinical trial for arbaclofen failed
to fulfill its initial endpoints and had to be terminated by
Seaside Therapeutics due to resource limitations.4 Acamprosate,
with agonist properties on both GABAA and GABAB receptors,
was well tolerated and was found to significantly improve
social behavior and reduce inattention/hyperactivity in 12
fragile X children aged 6–17 years in a prospective open-
label 10-week trial. Additionally, an increase in brain-derived
3www.clinicaltrials.gov
4www.clinicaltrials.gov
neurotrophic factor (BDNF) in blood was observed with
treatment and might become a useful biomarker for future
clinical studies (Erickson et al., 2010, 2013). A double-blind,
placebo-controlled study will be needed to further assess the
effect of acamprosate. As a whole, it is hopeful that some of
the GABA receptor agonists may eventually become clinically
applicable.
Serotonin receptors/transporters
The serotonin (5-Hydroxytryptamine, 5-HT) system is involved
in various brain functions, including synaptic plasticity, learning
and memory (Matthys et al., 2011; Lesch and Waider, 2012;
Gellynck et al., 2013). It has been shown that 5-HT7 receptor
(agonist 8-OH-DPAT) activation could reverse mGluR-induced
AMPA receptor internalization and correct excessive mGluR-
LTD in hippocampal neurons of Fmr1 knockout mice, suggesting
that 5-HT receptors may represent a novel therapeutic target
for fragile X syndrome (Costa et al., 2012). Interestingly, a
recent study has demonstrated that compounds activating 5-
HT2B receptors or inhibiting 5-HT2A receptors could enhance
phosphoinositide 3-kinase (PI3K) signaling transduction and
AMPA GluR1 dependent synaptic plasticity, and restore learning
in Fmr1 knockout mice, further linking 5-HT receptors to fragile
X syndrome (Lim et al., 2014).
The alteration of 5-HT and its transporters have been known
to associate with autism (Chugani, 2002; Devlin et al., 2005;
Prasad et al., 2009; Veenstra-VanderWeele et al., 2012; Harrington
et al., 2013). 5-HT transporters are the main target for widely used
antidepressant agents including fluoxetine (Wong et al., 2005).
Fluoxetine binds to 5-HT transporters and blocks 5-HT uptake
from the synaptic cleft into presynaptic vesicles in the central
nervous system (Wong et al., 2005; Tavoulari et al., 2009). Studies
have suggested that fluoxetine may be beneficial to individuals
with autism (Hollander et al., 2005, 2012; Kolevzon et al., 2006).
Treatment with fluoxetine has shown some effect in fragile X
mice and patients (Hagerman et al., 1999; Uutela et al., 2014).
However, fluoxetine has some possible side effects in clinic, such
as mood changes, agitation, restlessness, and aggression, and may
not be suitable to all individuals with fragile X syndrome and
other ASDs (Wernicke, 2004; Kolevzon et al., 2006; Uutela et al.,
2014).
Dopamine receptors
Dopamine plays critical roles in synaptic plasticity, cognitive
functioning and neuropsychiatic pathologies (Jay, 2003; Seamans
and Yang, 2004; Surmeier et al., 2009; Cerovic et al., 2013).
Deficits in the dopamine system have been demonstrated in
both fragile X animal models and patients (Roberts et al., 2005;
Wang et al., 2008b; Weinshenker and Warren, 2008; Fulks et al.,
2010; Paul et al., 2013; Rogers et al., 2013). Electrophysiological
studies have found that dopaminergic modulation of synaptic
transmission and potentiation are impaired in fragile X mice
(Wang et al., 2008b; Paul et al., 2013). Biochemical studies
have further revealed that dopamine D1 receptor mediated
synapse-associated protein synthesis, AMPA GluR1 receptor
surface expression and subsequent internalization are defective
in these mice (Wang et al., 2008b, 2010a). Application of
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the D1 receptor agonist and/or D2 receptor antagonist could
promote PI3K signaling and AMPA GluR1 receptor delivery,
and improve learning behaviors in Fmr1 knockout mice (Lim
et al., 2014). The dopamine D1 receptor agonist also partially
rescued the hyperactivity and enhanced motor function of
fragile X mice (Wang et al., 2008b). These findings suggest
that dopamine receptors could be a potential target for
effectively treating cognitive impairment associated with fragile
X syndrome.
Cannabinoid receptors
The endocannabinoids N-arachidonoyl ethanolamine and 2-
arachidonoyl glycerol (2-AG) activate cannabinoid receptors
(CB1R and CB2R), and modulate synaptic plasticity and
cognitive function (Chevaleyre et al., 2006; Heifets and Castillo,
2009; Oudin et al., 2011). Alterations in endocannabinoid
signaling contribute to cognitive dysfunction associated with
fragile X syndrome. Various abnormalities in endocannabinoid
signaling, such as CB1R-driven long-term regulation of synaptic
strength due to mGluR5 activation, have been observed in
several brain areas of Fmr1 knockout mice (Maccarrone et al.,
2010; Zhang and Alger, 2010; Busquets-Garcia et al., 2013).
FMRP exerts a regulatory control over the endocannabinoid
system at central synapses (Maccarrone et al., 2010). Loss of
FMRP affects endocannabinoid signaling, possibly through
local 2-AG production (Straiker et al., 2013). In fragile X
mice, the linkage between mGluR5 and the 2-AG producing
enzyme, diacylglycerol lipase-α (DGL-α), is disrupted
and mGluR5-dependent 2-AG formation is compromised,
leading to impairment of endocannabinoid-mediated LTD
in the ventral striatum and prefrontal cortex (Jung et al.,
2012).
Pharmacological enhancement of 2-AG signaling by inhibiting
2-AG-deactivating enzyme monoacylglycerol lipase (MGL)
with JZL184, normalized this synaptic defect and corrected
behavioral abnormalities (hyperactivity and abnormal anxiety)
in fragile X mice (Jung et al., 2012). Interestingly, dampening
of endocannabinoid signaling through pharmacological or
genetic approaches also benefit these mice. CB1R blockade
with rimonabant or genetic reduction of CB1R, normalized
cognitive impairment, nociceptive desensitization, susceptibility
to audiogenic seizures, overactivated mTOR signaling and altered
spine morphology in the male Fmr1 knockout (Fmr1(-/y)) mice,
whereas CB2R antagonism with AM630 normalized anxiolytic-
like behaviors in those mice (Busquets-Garcia et al., 2013).
These studies thus demonstrate that targeting endocannabinoid
signaling might provide a new therapeutic strategy for fragile
X syndrome. Further investigation is needed to clarify the
therapeutic value of this potential target.
Muscarinic acetylcholine receptors
The G-protein coupled muscarinic acetylcholine receptors
(mAChRs, subtypes M1–M5) are widely expressed in the
central nervous system and mediate the metabotropic actions of
acetylcholine (Volpicelli and Levey, 2004; Picciotto et al., 2012).
M1 mAChR activation facilitates synaptic plasticity, learning
and memory. Activation of M1 mAChRs stimulates synthesis of
synaptic proteins including FMRP, and induces protein synthesis
dependent LTD similar to group 1 mGluR-LTD (McCoy and
McMahon, 2007; Volk et al., 2007). In the absence of FMRP,
hippocampal M1 mAChR-dependent LTD is enhanced, indicating
overactive mAChR signaling in Fmr1 knockout mice (Volk et al.,
2007). Genetic reduction of M4 mAChRs corrected the analgesic
response and partly rescued the acoustic startle response in Fmr1
knockout mice (Veeraragavan et al., 2012). These studies suggest
new therapeutic strategies for using mAChR antagonists in fragile
X syndrome.
The subtype selective mAChR modulators, including the M1
receptor antagonist dicyclomine and M4 receptor antagonist
tropicamide, have been tested in the fragile X mouse model.
The M1 receptor antagonist dicyclomine decreased repetitive
and/or perseverative behavior (marble burying) and reduced
susceptibility to audiogenic seizures in Fmr1 knockout mice
(Veeraragavan et al., 2011b). Similarly, the M4 receptor
antagonist tropicamide also attenuated audiogenic seizure
susceptibility in Fmr1 knockout mice (Veeraragavan et al., 2011a).
Noteworthy, treatment with tropicamide reduced repetitive
and/or perseverative behaviors, improved performance in the
passive avoidance task in both wild-type and fragile X mice, and
reduced audiogenic seizures in fragile X mice (Veeraragavan et al.,
2011a). These studies indicate that pharmacological inhibition
of mAChRs modulates specific behavioral responses and further
support these receptors as therapeutic targets for fragile X
syndrome.
Oxytocin receptors
Oxytocin acts as a neuromodulator through its receptors in
various brain areas and regulates social cognition and behaviors
(Neumann, 2008; Meyer-Lindenberg et al., 2011; Neumann and
Landgraf, 2012; Knobloch and Grinevich, 2014). It is emerging
as a target for treatment of anxiety and depression-related
diseases or social dysfunction including autism (Neumann,
2008; Meyer-Lindenberg et al., 2011; Neumann and Landgraf,
2012; Anagnostou et al., 2014a; Preti et al., 2014). The
perinatal excitatory-to-inhibitory shift of GABA is mediated
by oxytocin receptors. Oxytocin-mediated GABA inhibition
during delivery could attenuate autism pathogenesis in rodent
offsprings. Application of the oxytocin receptor antagonist
SSR126768A in naïve mothers could produce offspring which
have the electrophysiological and behavioral autistic-like features
(Tyzio et al., 2014). In fragile X mice, oxytocin is reduced in
some brain regions and the oxytocin-mediated neuroprotective
GABA excitatory-inhibitory shift during delivery is absent (Tyzio
et al., 2014). This study thus indicates the importance of the
oxytocin system in the pathogenesis of autism and fragile X
sydrome.
The clinical actions of oxytocin have been validated in
ASD patients, providing preliminary evidence that oxytocin is
able to enhance brain function and improve social behaviors
in autistic patients (Andari et al., 2010; Domes et al., 2013;
Gordon et al., 2013; Anagnostou et al., 2014a; Preti et al.,
2014; Scheele et al., 2014; Watanabe et al., 2014). Intranasal
administration of oxytocin could ameliorate symptoms of social
anxiety in children with fragile X syndrome (Hall et al., 2012).
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The double-blind placebo-controlled studies of oxytocin will
be needed for further validation of its effect on fragile X
patients.
AMPA receptors
The surface expression and synaptic delivery of AMPA receptors
(GluR1) is impaired in Fmr1 knockout mice, altering signal
transmission and synaptic plasticity (Nakamoto et al., 2007; Hu
et al., 2008; Suvrathan et al., 2010; Wang et al., 2010a). AMPA
receptor modulators have been tested in fragile X patients. CX516
is a positive allosteric modulator that potentiates glutamate
activation with the final outcome of strengthening synapses
(O’Neill et al., 2004; O’Neill and Witkin, 2007). In a double-
blind placebo-controlled trial in adult patients with fragile X
syndrome, 4-week treatment with CX516 produced no significant
improvement in cognitive or behavioral measures (Berry-Kravis
et al., 2006). The failure could be due to the potency of CX516 or
its dosage which may be inadequate for a therapeutic effect. It is
thus unclear whether modulation of AMPA receptors is a feasible
therapeutic strategy for treatment of fragile X syndrome.
NMDA receptors
The defects in NMDA receptors observed in the hippocampus,
prefrontal cortex and other brain areas of fragile X mice are
believed to contribute to fragile X phenotypes (Pilpel et al., 2009;
Suvrathan et al., 2010; Krueger et al., 2011; Yun and Trommer,
2011; Eadie et al., 2012; Gocel and Larson, 2012). Memantine is an
uncompetitive NMDA receptor antagonist and has been shown to
improve language function and social behavior in autistic patients
(Erickson and Chambers, 2006; Chez et al., 2007; Niederhofer,
2007). A study in cultured cerebellar granule cells from Fmr1
knockout mice suggested that memantine may exert therapeutic
capacity for fragile X syndrome through a stimulatory effect
on dendritic spine maturation and excitatory synapse formation
(Wei et al., 2012). Although a pilot study showed that memantine
was modestly effective in several patients with fragile X syndrome,
a systematic clinical study is needed to further evaluate its
effectiveness (Erickson et al., 2009).
TARGETING SIGNALING PATHWAYS DOWNSTREAM OF
NEUROTRANSMITTER RECEPTORS
Studies in fragile X animal models have revealed defects
in intracellular signaling pathways [Mitogen-activated protein
kinases (MAPKs), PI3K, mTOR and glycogen synthase kinase-
3 (GSK3)] which could be downstream of neurotransmitter
receptors such as glutamate, GABA, endocannabinoid, 5-HT,
dopamine or mACh receptors. These signaling pathways may
serve as therapeutic targets for fragile X syndrome (Figure 1;
Tables 1, 2).
Mitogen-activated protein kinases
MAPKs are a family of serine/threonine protein kinases, including
ERKs, p38 MAPKs, and c-Jun N-terminal kinase (JNK; Wang
and Zhuo, 2012). The ERK1/2 pathway, which is activated by the
Ras-mitogen-activated protein kinase/ERK kinase (MEK) and
eventually leads to gene transcription or mRNA translation, plays
critical roles in synaptic plasticity (Kelleher et al., 2004; Thomas
and Huganir, 2004; Wiegert and Bading, 2011; Wang and Zhuo,
2012). A number of studies have investigated ERK signaling
under basal conditions or upon mGluR-induction using brain
tissues from fragile X animal models or patients (Kim et al., 2008;
Weng et al., 2008; Wang et al., 2012b; Curia et al., 2013). Although
these studies sometimes have presented conflicting results, most
of them have shown that the ERK1/2 pathway is altered in fragile
X conditions, suggesting that the ERK pathway is likely to have
translational implications for fragile X syndrome (Weng et al.,
2008; Wang et al., 2012b; Curia et al., 2013). Indeed, treatment
with MEK1/2 inhibitor SL327 could prevent audiogenic seizures
in Fmr1 knockout mice (Wang et al., 2012b). Inhibition of
ERK1/2 with the MEK1/2-ERK1/2 inhibitor U0126 also reduced
elevated protein synthesis in hippocampus of fragile X mice
(Osterweil et al., 2010). These findings further support that
ERK1/2 pathway and the neurotransmitter systems that stimulate
ERK1/2 may represent additional therapeutic targets for fragile
X syndrome. Interestingly, statins, drug widely prescribed to treat
hypercholesterolemia, have shown potentials for treating fragile X
syndrome. Lovastatin corrected the excess protein synthesis and
the exaggerated mGluR-LTD in the hippocampal slices of Fmr1
knockout mice, attenuated hyperexcitability in visual cortex,
and reduced audiogenic seizures in those mice (Osterweil et al.,
2013). In a recent Phase I clinical trial, lovastatin was found to
improve aberrant behaviors (social avoidance/unresponsiveness,
stereotypy, hyperactivity and irritability) in majority (12/15)
of fragile X patients after 12-weeks of treatment; the effect was
significant after 4-week treatment at the lower dose, with further
improvement during the 4–12 week treatment (Çaku et al.,
2014). Although it was suggested that statins may alter membrane
cholesterol and lipid rafts, thus modulating group I mGluRs
or/and other neurotransmitter systems to correct fragile X
phenotypes, the drugs might also exert the effects through direct
inhibition of Ras–ERK activity (Kumari et al., 2013; Osterweil
et al., 2013; Wang, 2014).
The JNK pathway is known to regulate mGluR-dependent
gene transcription (Wang and Zhuo, 2012). A recent study has
shown that JNK is essential for mGluR-dependent expression of
FMRP target proteins. In addition, JNK activity is upregulated
in synapses of Fmr1 knockout mice, and inhibition of JNK
with SP600125 decreased elevated postsynaptic protein synthesis
in these mice, suggesting that JNK could be a key signaling
downstream of mGluR in regulating FMRP-dependent protein
synthesis and may provide a strategy to restore the deficits in
fragile X syndrome (Schmit et al., 2013).
Phosphoinositide 3-kinase
PI3K transduces signals from cell surface receptors to the
Akt/mTOR pathway and is essential for dendritic spine
development and synaptic plasticity underlying learning
and memory (Horwood et al., 2006; Hu et al., 2008; Cuesto
et al., 2011). The PI3K catalytic subunit p110beta can be
regulated by FMRP. Both p110beta level and PI3K activity
are elevated and insensitive to mGluR stimulation in Fmr1
knockout neurons, suggesting that dysregulated PI3K signaling
may underlie synaptic deficits in fragile X syndrome (Gross
et al., 2010; Gross and Bassell, 2014). PI3K inhibitor LY294002
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corrected dysregulated synaptic protein synthesis, excess AMPA
receptor internalization and the increased spine density in Fmr1
knockout neurons, supporting PI3K as a potential therapeutic
target for fragile X syndrome (Gross et al., 2010). Development
of specific inhibitors for PI3K subunits may help to translate
this strategy to patients since selective inhibition of the p110b-
subunit with TGX-221 has been found to rescue excess protein
synthesis in synaptoneurosomes from fragile X mice and in
patient cells (Gross et al., 2010; Gross and Bassell, 2012, 2014).
Conversely, one recent study showed that promoting PI3K
signaling by dipotassium bisperoxo (5-hydroxypyridine-2-
carboxyl)oxovanadate (BpV), a phosphatase and tensin homolog
(PTEN) inhibitor, reversed deficits in both basal turnover and
activity-mediated spine stabilization in hippocampal slices,
restored defective long-term potentiation (LTP) mechanisms in
slices and improved reversal learning in Fmr1 knockout mice
(Boda et al., 2014). Thus, the specific role of PI3K signaling in
fragile X syndrome needs to be further investigated due to the
complexity of its upstream cell surface receptors and interactions
with other signaling pathways.
Mammalian target of rapamycin
The mTOR signaling cascade controls initiation of cap-dependent
translation (Hay and Sonenberg, 2004; Narayanan et al., 2008;
Hoeffer and Klann, 2010). Its downstream effector ribosomal
protein S6 kinase (S6K1) is a regulator of translation initiation
and elongation in cap-dependent protein synthesis (Narayanan
et al., 2008; Hoeffer and Klann, 2010). S6K1 is a major kinase
which phosphorylates and regulates FMRP following group
1 mGluR or dopamine D1 receptor activation (Narayanan
et al., 2008; Wang et al., 2010a). The basal levels of mTOR
phosphorylation and activity were found to be elevated in the
hippocampus of Fmr1 knockout mice (Sharma et al., 2010). In
addition, group 1 mGluR activation of mTOR is absent is those
mice (Ronesi and Huber, 2008b). The misregulation of mTOR
signaling was also observed in fragile X patients (Hoeffer et al.,
2012), suggesting that mTOR could be a target or biomarker for
treatment of fragile X syndrome.
Treatment of Fmr1 knockout mice with temsirolimus, an
mTOR inhibitor, prevented object recognition memory deficits
and reduced audiogenic seizure susceptibility in those mice
(Busquets-Garcia et al., 2013). Elevated phosphorylation of
translational control molecules and exaggerated protein synthesis
in fragile X mice were corrected through the targeting of
S6K1. Genetic deletion of S6K1 also prevented a broad range
of fragile X phenotypes, including exaggerated translation,
enhanced mGluR-LTD, abnormal dendritic spine morphology,
several behavioral characteristics and peripheral features (weight
gain and macroorchidism) (Bhattacharya et al., 2012). Notably,
administration of the mTORC1 (mTOR complex 1) inhibitor
rapamycin improved sociability in the BTBR mouse model of
ASDs (Burket et al., 2014); targeting downstream mTOR signaling
such as eukaryotic translation initiation factor 4E (eIF4E) also
reversed autism (Gkogkas et al., 2013; Wang and Doering, 2013).
These studies thus support that mTOR signaling represents a
potential therapeutic target for fragile X syndrome and other
ASDs.
Glycogen synthase kinase-3
GSK3 is a serine/threonine kinase that exists in two isoforms
(GSK3α and GSK3β) and regulates many cellular processes
through phosphorylation of their substrates. The activity of
GSK3 itself is controlled by inhibitory serine phosphorylation
induced by various intracellular pathways including PI3K/Akt
and MEK/ERK that converge on GSK3 (Cohen and Goedert,
2004; Jope and Roh, 2006; Sugden et al., 2008). In Fmr1
knockout mice, GSK3 phosphorylation was reduced in several
brain regions resulting in elevated GSK3 signaling (Min et al.,
2009; Mines et al., 2010; Yuskaitis et al., 2010). Lithium, a
classical drug for psychiatric disorders, is a GSK3 inhibitor
that both increases the inhibitory serine-phosphorylation
of GSK3 and directly inhibits GSK3 activity (Chiu and
Chuang, 2010; Mines and Jope, 2011). Since lithium has
many other off-target effects including inhibition of inositol
monophosphatase, more selective GSK3 inhibitors have been
developed (Chiu and Chuang, 2010; Mines and Jope, 2011).
Lithium, as well as the selective GSK3β inhibitor SB216763,
was found to be able to correct mutant phenotypes (audiogenic
seizure susceptibility and hyperactivity) of Fmr1 knockout
mice. Particularly, lithium remained effective with chronic
administration (Min et al., 2009). Acute or chronic lithium
treatment could increase inhibitory serine phosphorylation of
GSK3 in mouse brain; chronic treatment ameliorated alterations
in open-field activity, elevated plus-maze and passive avoidance
and impaired cognition in fragile X mice (Yuskaitis et al.,
2010; King and Jope, 2013). Chronic treatment with SB216763
corrected hippocampus-dependent learning deficits as well as
defects in adult neurogenesis in the hippocampus of fragile x mice
(Guo et al., 2012). The specific GSK3 inhibitors TDZD-8 and
VP0.7 corrected impairments in hippocampus-related cognitive
tasks. Furthermore, the improvements in behaviors correlated
to the rescue of deficits in NMDA receptor dependent LTP in
the hippocampus of Fmr1 knockout mice as a result of GSK3
inhibition (Franklin et al., 2014). These studies thus support that
targeting GSK3 may provide therapeutic benefits for fragile X
syndrome.
In an open-label trial in 15 patients, the two month treatment
with lithium was well-tolerated and had positive effects on
behavior and adaptive skills in fragile X syndrome (Berry-Kravis
et al., 2008). The placebo-controlled trials of lithium or other
GSK3 inhibitors in fragile X syndrome will be warranted.
TARGETING PROTEINS REGULATED BY FMRP
Matrix metalloproteinase 9
Matrix metalloproteinases (MMPs) are a family of extracellular
proteases that are involved in synaptogenesis, neurotransmission
and synaptic plasticity (Ethell and Ethell, 2007; Wright and
Harding, 2009; Huntley, 2012). MPP9 mRNA is among the
putative mRNA targets of FMRP with increased translation in
the absence of FMRP (Janusz et al., 2013). MMP9 is necessary
for the development of fragile X phenotypes. Genetic deletion
of MMP9 rescued key features of fragile X syndrome, including
dendritic spine abnormalities, exaggerated mGluR-LTD, aberrant
cognitive and social behaviors as well as macroorchidism in the
mouse model (Sidhu et al., 2014). Minocycline, a tetracycline
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analogue with anti-inflammatory and antiapoptotic activity, has
been used to inhibit MMP9 (Bilousova et al., 2009; Siller and
Broadie, 2012). Treatment of young mice with minocycline
increased phosphorylation and subsequent membrane insertion
of AMPA GluR1 receptors (Imbesi et al., 2008). Minocycline
rescued maturation of dendritic spines in the hippocampus
thereby correcting the spine phenotype in Fmr1 knockout mice
(Bilousova et al., 2009). In addition, chronic minocycline reduced
anxiety-related behavior, improved cognitive function in young
Fmr1 knockout mice (Bilousova et al., 2009), and reversed
impaired social communication during mating among fragile
X mice (Rotschafer et al., 2012). In comparison of the effect
of minocycline on young and adult fragile X mice, it was
found that minocycline could reduce locomotor activity in both
young and adult mice, some behavioral improvements could
be long-lasting in young mice, but not in adults. In addition,
minocycline reduced audiogenic seizure susceptibility in young
mice (Dansie et al., 2013). This study provides further evidence
that minocycline can produce long-lasting benefits in the fragile
X animal model.
Clinical trials have been conducted to evaluate the safety
and efficacy of minocycline. An open-label add-on pilot trial
demonstrated that minocycline is well tolerated and can provide
significant functional benefits to fragile X patients (Paribello
et al., 2010). In a controlled clinical trial, minocycline treatment
was observed to lower the elevated plasma activity of MMP9
in individuals with fragile X syndrome. In some cases, changes
in MMP9 activity were found to be positively associated with
improvement in clinical measures (Dziembowska et al., 2013).
In another randomized, double-blind, placebo-controlled and
crossover trial, minocycline treatment administered for 3 months
was found to be safe and produce greater global improvement
than a placebo in children with fragile X syndrome (Leigh et al.,
2013). However, longer trials are warranted to further assess the
benefits and side effects related to minocycline.
p21-activated kinase
The small GTPase Rac1 and its effector p-21 activated kinase
(PAK) are critical for regulation of actin polymerization, dendritic
spine morphogenesis and synaptic plasticity (Hayashi et al.,
2004; Zhang et al., 2005; Kreis and Barnier, 2009; Murata
and Constantine-Paton, 2013). In hippocampal synapses of
Fmr1 knockout mice, physiological activation of the Rac-PAK
signaling pathway is impaired (Chen et al., 2010). FMRP directly
interacts with PAK1. Inhibition of PAK activity by expression
of the dominant negative PAK (dnPAK) transgene results in a
dendritic spine phenotype opposite to that of fragile X syndrome
(Hayashi et al., 2007). A genetic expression of dnPAK in Fmr1
knockout mice at least partially corrected abnormalities in spine
length and density in the cortex, and fully restored deficits
in cortical LTP. Additionally, several behavioral abnormalities
including hyperactivity, stereotypy, anxiety, and deficits in trace
fear memory were ameliorated (Hayashi et al., 2007). This genetic
rescue of fragile X phenotypes in the mouse model suggests that
the PAK signaling pathway could be a novel intervention site for
fragile X syndrome and autism. Pharmacological treatment with
the PAK inhibitor FRAX486 reversed dendritic spine phenotypes,
and rescued seizures and behavioral abnormalities such as
hyperactivity and repetitive movements in Fmr1 knockout mice,
further supporting PAK as a therapeutic target. Importantly, these
effects could be achieved in adult Fmr1 knockout mice with a
single administration of FRAX486, demonstrating the potential
for therapy in adults with fragile X syndrome (Dolan et al., 2013).
Amyloid precursor protein
Amyloid precursor protein (APP) is a transmembrane protein
that plays roles in synaptogenesis and synaptic plasticity (Gralle
and Ferreira, 2007; Randall et al., 2010; Nalivaeva and Turner,
2013). APP is translated upon mGluR5 activation. FMRP binds
to APP mRNA and controls its translation (Westmark and
Malter, 2007). Absence of FMRP leads to APP overexpression
and diminished mGluR-induced synthesis (Westmark and Malter,
2007). Cleavage of APP can produce β-amyloid (Aβ), which is
overexpressed in the brain of Fmr1 knockout mice, suggesting
a pathogenic role in fragile X syndrome (Westmark et al.,
2010). Genetic reduction of APP/Aβ could partially or completely
correct characteristic fragile X phenotypes, including audiogenic
seizures, anxiety, dendritic spine morphology and exaggerated
mGluR-LTD (Westmark et al., 2011), suggesting drugs directed at
reducing Aβ in Alzheimer disease such as the secretase inhibitors
or β-site APP cleaving enzyme (BACE-1) inhibitors may be
applicable to fragile X syndrome (Malter et al., 2010; Westmark,
2013; Westmark et al., 2013).
Striatal-enriched protein tyrosine phosphatase
STEP, a brain-specific protein tyrosine phosphatase,
dephosphorylates key signaling proteins including ERK1/2,
p38 MAPK, the tyrosine kinase Fyn, and surface AMPA and
NMDA receptors, thereby inactivating the kinases or promoting
endocytosis of the receptors and opposing development of
synaptic strengthening (Braithwaite et al., 2006; Goebel-Goody
et al., 2012b). STEP is translated upon mGluR5 activation and
mediates AMPA receptor internalization during mGluR-LTD
(Zhang et al., 2008; Goebel-Goody and Lombroso, 2012). FMRP
interacts with the transcript encoding STEP. The basal level
of STEP is elevated and mGluR-dependent STEP synthesis is
absent in Fmr1 knockout mice (Goebel-Goody et al., 2012a). It is
possible that the synaptic deficits and behavioral abnormalities in
fragile X syndrome may be linked to the dysregulation of STEP
(Goebel-Goody and Lombroso, 2012). Genetic reduction of STEP
could attenuate audiogenic seizures, improve characteristic social
abnormalities, and reverse anxiety-related behaviors in Fmr1
knockout mice, suggesting that STEP might be a therapeutic
target for treating fragile X patients (Goebel-Goody et al., 2012a).
Potassium channels
Potassium channels control the resting membrane potential and
modulate the action potential waveform, mediating homeostasis
of neuronal excitability (Misonou, 2010; Lee and Jan, 2012; Kim
and Kaczmarek, 2014). In fragile X animal models, defects have
been found in several types of potassium channels, such as the
sodium-activated potassium Slack (Brown et al., 2010; Zhang
et al., 2012), voltage-gated potassium channels Kv3.1b (Strumbos
et al., 2010) and Kv4.2 (Gross et al., 2011; Lee et al., 2011), and
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large-conductance calcium-activated potassium (BK) channels
(Deng et al., 2013; Zhang et al., 2014b).
FMRP interacts directly with Slack channels to enhance
the channel activity, raising the possibility that Slack-FMRP
interaction may link patterns of neuronal firing with changes
in protein translation (Brown et al., 2010; Zhang et al., 2012).
Disturbance of this link when FMRP is absent may underlie
altered neuronal networks in fragile X syndrome. FMRP binds the
mRNAs encoding Kv3.1b and is required for rapid experience-
dependent regulation of Kv3.1b (Strumbos et al., 2010). FMRP
also regulates mRNA translation and protein expression of
Kv4.2; absence of FMRP-mediated control of Kv4.2 might
contribute to excess neuronal excitability in Fmr1 KO mice
(Gross et al., 2011). Recovery of Kv4.2 after NMDA receptor-
mediated degradation also requires FMRP, probably due to
NMDA receptor activation-induced FMRP dephosphorylation,
which turns off FMRP suppression of Kv4.2 (Lee et al., 2011).
Significantly, treating hippocampal slices of fmr1 KO mice with
Kv4 channel blocker HpTx2 restored LTP induced by moderate
stimuli, suggesting that potassium channels as an FMRP target
could be of potential relevance to fragile X therapy (Lee
et al., 2011). FMRP modulates action potential duration via its
interaction with beta4 subunits of BK channels, thus regulating
neurotransmitter release and synaptic transmission. Loss of
these FMRP functions might be responsible for dysregulation
of synaptic transmission in fragile X syndrome (Deng et al.,
2013). Interestingly, a recent study showed that a selective BK
channel opener (BMS-204352) could rescue multiple behavioral
impairments (social, emotional and cognitive) in fragile X mice
(Hebert et al., 2014), further demonstrating that potassium
channels may open up new opportunities for treating fragile X
syndrome.
In summary, multiple targeted pharmacological treatments
have been found to rescue the phenotypes of fragile X animal
models, but few have been beneficial to patients. Acamprosate,
lovastatin, lithium and minocycline are the drugs that can
be currently prescribed and have shown benefits to patients
with fragile X syndrome. However, each single drug may not
be effective for all patients. The combination of different
drug therapies, together with behavioral interventions, will be
necessary for better efficacy in treating fragile X syndrome (Braat
and Kooy, 2014; Hagerman et al., 2014; Hagerman and Polussa,
2015).
TARGETED PHARMACOTHERAPY FOR RETT SYNDROME
RTT is a postnatal neurodevelopmental disorder that occurs
mainly in females and is the leading cause of intellectual disability
in this gender (Hagberg et al., 1983; Laurvick et al., 2006;
Neul et al., 2010). Clinical presentation occurs in stages with
an initial developmental stagnation that is followed by a rapid
regression during which RTT individuals have autistic features,
stereotypic hand movements, loss of language, and develop
aggressive behaviors (Chahrour and Zoghbi, 2007; Percy et al.,
2010). RTT girls also have seizures during childhood, daytime
breathing arrythmias, dysautonomia, and develop scoliosis at
later stages, which also include Parkinsonian features and loss of
mobility (Glaze et al., 2010; Neul et al., 2014).
Loss-of-function mutations in the X-linked gene MECP2
(methyl-CpG-binding protein-2) are responsible for RTT (Amir
et al., 1999). In 95% of classic RTT cases, MECP2 mutations
occur de novo in germ cells and are usually on the paternal side
(Girard et al., 2001; Trappe et al., 2001; Bienvenu and Chelly,
2006). There is a spectrum of mutations ranging from missense,
nonsense, and frameshift mutations (Moretti and Zoghbi, 2006).
RTT individuals appear to have a typical development until
6–18 months of age, when they start missing developmental
milestones. The MECP2 gene encodes a predominantly nuclear
protein that is expressed ubiquitously but with predominance
in the brain (Klose and Bird, 2006). The expression of MECP2
follows a temporal pattern: it peaks in the early postnatal
period when maturation of neurons and activity dependent
refinement of synapses occurs (LaSalle et al., 2001; Shahbazian
et al., 2002; Cohen et al., 2011). Its expression remains elevated
during adulthood, when it is involved in the maintenance of
existing neurons and synapses. MeCP2 was initially identified
as a transcriptional repressor through its binding to methylated
CpG sites in gene promoters (Nan et al., 1998; Jung et al.,
2003), although it regulates gene expression through multiple
mechanisms (Guy et al., 2011).
From multiple studies using different knockout mouse models,
converging data indicates that the pathological deficit in RTT is
at the microcircuit level involving the structure and function of
synapses that are critical for synaptic transmission and plasticity
(Chen et al., 2001; Guy et al., 2001, 2007; Figure 2). Therefore,
most therapeutic treatments revolve around the restoration of
synaptic function and maturation (Gadalla et al., 2011). Current
preclinical research on therapeutic strategies and human clinical
trials can be divided into drugs that target the primary cause,
i.e., loss-of-function mutations in MECP2, and drugs that target
downstream consequences, including neurotransmitter receptor
systems, neurotrophins, and their intracellular signaling pathways
(Tables 3, 4). Since this review is focused on pharmacological
treatments, genetic manipulations will not be discussed here and
readers are directed to recent reviews on this topic (Cobb et al.,
2010; Gadalla et al., 2011; Guy et al., 2011). Treatment paradigms
that have targeted pathways downstream of the Mecp2 gene in
mice, and the current human clinical trials are discussed in detail
below.
GROWTH AND NEUROTROPHIC FACTORS
Brain-derived neurotrophic factor
Bdnf, the gene encoding the BDNF protein, is one of the first
recognized direct targets of MeCP2 transcriptional regulation
(Chen et al., 2003; Martinowich et al., 2003). BDNF binds
to the high affinity receptor tropomyosin-related kinase B
(TrkB), which activates intracellular signaling cascades critical
for neuronal development, synaptic maturation, and learning
and memory, like PLCγ-IP3R, PI3K-Akt, and MAPK-CREB
(Segal and Greenberg, 1996). Bdnf expression is controlled by
MeCP2 through complex interactions (Chen et al., 2003; Chang
et al., 2006; Li and Pozzo-Miller, 2014), and reduced levels of
BDNF mRNA and protein are considered to contribute to the
pathophysiological mechanisms of RTT disease progression
(Katz, 2014). Over-expression of BDNF in excitatory forebrain
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FIGURE 2 | Dendritic spines in Rett syndrome (RTT). Proposed intracellular
mechanisms that mediate the effects of BDNF/TrkB on dendritic spine
density and morphology. Trk receptors are activated upon binding of
neurotophic factors, leading to dimerization and auto-phosphorylation. This
process allows for the intracellular binding of adaptor proteins to Trk and
activation of major pathways including Ras/ERK, PI3K, and PLCγ.
Components of each of these three pathways have been implicated in the
effects of BDNF on dendritic spines (highlighted in red text). Potential
therapies for the treatment of RTT act on these pathways (highlighted in
green text)—LM22A-4 directly phosphorylates TrkB and [1,3]IGF-1 activates
the PI3K and Ras/ERK pathways. Abbreviations: AKT(PKB), protein kinase B;
AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;
BDNF, brain-derived neurotrophic factor; CaMK, Ca2+/calmodulin-dependent
protein kinase; cAMP, cyclic adenosine monophosphate; CREB, cAMP
response element-binding protein; DAG, diacylglycerol; Frs2, fibroblast
growth factor receptor substrate 2; GAB1, GRB2-associated-binding protein
1; Grb2, growth factor receptor-binding protein 2; IGF-1, insulin-like growth
factor 1; IGF-1R, IGF-1 receptor; IP3, inositol triphosphate; MAPK,
mitogen-activated protein kinase; MEK, MAPK//ERK kinase; NMDAR,
N-methyl-D-aspartate receptor; PI3K, phosphoinositide 3-kinase; PIP2,
phospohatidylinositol 4, 5 bisphosphate; PKC, protein kinase C; PLCγ,
phospholipase C-γ; Raf, proto-oncogenic serine/threonine protein kinase; Ras,
rat sarcoma proto-oncogenic G-protein; SHC, SH-2-containing protein; SH-2,
src homology domain 2; SOS, nucleotide exchange factor son of sevenless;
TrkB, tropomyosin related kinase B receptor; TRPC, transient receptor
potential channel.
neurons of Mecp2 deficient mice improved their RTT-like
neurological phenotypes (Chang et al., 2006). Over-expression
of BDNF rescued dendritic atrophy caused by shRNA-mediated
Mecp2 knockdown in cultured hippocampal neurons (Chapleau
et al., 2009). The main limitation of recombinant BDNF is its low
blood-brain barrier permeability, which prompted the search for
BDNF “boosters” or mimetics with sufficient bioavailability in
brain.
Currently, there are two clinical trials in RTT individuals
testing compounds that boost BDNF levels: a Phase-1 open
label trial of Fingolimod, and a Phase-2 open label trial of
glatiramer acetate (Copaxone), both FDA-aproved drugs for the
treatment of multiple sclerosis. Fingolimod is a modulator of the
sphingosine-1 phosphate receptor, which leads to an increase in
BDNF expression and activation of TrkB downstream signaling
pathways (Deogracias et al., 2012). Glatiramer acetate is an
immunomodulatory agent based on the amino acid structure
of myelin basic protein (MBP) that is currently used for the
treatment of relapsing-remitting multiple sclerosis. One of the
proposed mechanisms of action of Copaxone is the increased
expression and release of BDNF by autoreactive T-cells (Ziemssen
et al., 2002).
Additonal potential leads with preclinical evidence include
ampakines, which are known to increase BDNF expression by
their action on AMPA-type glutamate receptors (Lauterborn
et al., 2003). Peripheral treatment with ampakines significantly
improved respiratory dysfunction in male Mecp2 knockout mice
(Ogier et al., 2007) that model the recurrent apneas suffered by
RTT girls. Cysteamine and its dimer cystamine increase BDNF
levels (Borrell-Pagès et al., 2006), which supports the Phase-2/3
clinical trial of RP103 for Huntington’s disease. More recently,
a small molecule BDNF loop mimetic (LM22A-4) designed in
silico to interact with the BDNF binding pocket in the TrkB
receptor (Massa et al., 2010), restored respiratory regularity in
female Mecp2 heterozygous mice (Schmid et al., 2012; Kron et al.,
2014).
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Table 3 | Current preclinical trials in Mecp2 deficient mice.
Agent or Approach Sponsor Action
BDNF boosters
LM22A-4 (BDNF loop
mimetic)
Sigma-Aldrich;
RSRT
Partial agonist of
TrkB receptors
Improves breathing
RP103 (cysteamine) Raptor
Pharmaceuticals
Increases BDNF
expression and release
Improves breathing
Serotonin agonists
Sarizotan Newron 5HT1 agonist
Pharmaceuticals Improves breathing
NLX-101 Neurolixis 5HT1 agonist
Improves breathing
NMDA receptors
GluN2A negative
allosteric
Mnemosyne
Pharmaceuticals
Improved visual
cortical functioning
modulator
Ketamine Approved drug Non-competitive NMDA
receptor antagonist
Improved respiratory
and locomotor function
Antidepressants
REV-003 Revive Atypical antidepressant
(Tianeptine) Therapeutics Improves breathing
MECP2 gene
Read-through compounds Research labs Skip premature STOP
codon in nonsense
mutations
Insulin Growth factor-1
Insulin Growth factor-1 (IGF-1) is a growth factor that, by
binding to the IGF-1 receptor, activates similar intracellular
signaling cascades to those triggered by BDNF activation of
TrkB receptors. Indeed, IGF-1 modulates synaptic plasticity
and neuronal maturation through a tyrosine kinase signaling
pathway that includes PI3K-Akt and MAPK (Zheng and Quirion,
2004). Unlike BDNF, IGF-1 permeability through the blood
brain barrier makes it an attractive compound for therapy.
Intraperitoneal injection of the active IGF-1 tripeptide (also
known as [1–3]IGF-1, or Glypromate) in male Mecp2 knockout
mice improved survival, locomotor activity, as well as social
and anxiety behaviors (Tropea et al., 2009). Full-length IGF-1
(Mecasermin) is already approved by the FDA for the treatment
of growth failure in children, and it was shown to have similar
effects in male Mecp2 knockout mice, as well as in female Mecp2
heterozygous mice (Castro et al., 2014); a cautionary note is
that full-length IGF-1 can worsen the metabolic syndrome of
Mecp2 deficient mice (Pitcher et al., 2013). The effects of full-
length IGF-1 are due to the direct activation of IGF-1 receptors
and its downstream signaling cascades, while the effects of the
[1–3]IGF-1 tripeptide may reflect increased expression of IGF-1
(Corvin et al., 2012), although its molecular mechanism-of-
action is currently unknown. Based on these promising leads,
a Phase-2 double-blinded placebo-controlled clinical trail is
underway to treat 3–10 years old RTT patients with full-length
IGF-1 (Khwaja et al., 2014). More recently, a Phase-2 double-
blinded placebo-controlled clinical trail in 16–45 years old RTT
individuals has been initiated to test the efficacy of NNZ-2566, a
protease-resistant analogue of the [1–3]IGF-1 tripeptide.
NEUROTRANSMITTER SYSTEMS
Monoamines
Multiple studies have documented low levels of monoamine
markers (dopamine, 5-HT, noradrenaline) in autopsy RTT brains
and in Mecp2 deficient mice (Brücke et al., 1987; Lekman et al.,
1989; Roux et al., 2008). Desipramine is an antidepressant that
blocks the uptake of noradrenaline, and has been shown to reverse
the depletion of tyrosine hydroxylase in the brainstem, helping
with the regulation of breathing and extending the life-span of
male Mecp2 knockout mice (Roux et al., 2007; Zanella et al.,
2008). Desipramine is currently in a Phase-2 double blinded,
placebo-controlled clinical trial for RTT. The atypical tricyclic
antidepressant tianeptine (REV-003) also improved respiratory
activity in Mecp2 deficient mice, although this effect may reflect
modulation of monoamine levels, glutamate receptor function, or
BDNF levels (McEwen et al., 2010). Recently, preclinical studies in
Mecp2 deficient mice have demonstrated that the 5-HT1a agonist
Sarizotan inhibited expiratory neuron activity, which significantly
improved breathing patterns and reduced the frequency of apneas
(Abdala et al., 2014).
Glutamate
The NMDA-type of glutamate receptors is altered in Mecp2
knockout mice (Blue et al., 1999, 2011; Maliszewska-Cyna et al.,
2010). Dextromethorphan is a NMDA receptor antagonist that
has been tried in an open label clinical trial without any significant
benefit. The FDA-approved NMDA receptor antagonist ketamine
has been useful in Mecp2 knockout mice to improve RTT-like
phenotypes (Kron et al., 2012); based on these encouraging
results, a clinical trial of low dose ketamine is currently planned.
A delay in the developmental switch in the expression of GluN2
subunits of the NMDA receptor in the visual cortex contributes
to visual acuity deficits in Mecp2 deficient mice, which were
improved by genetic deletion of the GluN2A subunit (Durand
et al., 2012); a negative allosteric modulator selective for GluN2A-
containing NMDA receptors is currently in preclinical trials in
Mecp2 deficient mice.
GABA
Several studies have shown that GABAergic signaling is impaired
in Mecp2 deficient mice, which alters the excitatory/inhibitory
balance. Impaired GABAergic inhibition was described in the
brainstem (Medrihan et al., 2008), thalamus (Zhang et al., 2010)
and hippocampus (Calfa et al., 2015), and involved impaired
evoked and spontaneous inhibitory synaptic transmission
and numbers of GABAergic synapses on principal neurons.
Furthermore, selective deletion of Mecp2 in GABAergic
neurons led to impaired GABAergic transmission, cortical
hyperexcitability and several neurological features of RTT and
ASDs (Chao et al., 2010). Also, deletion of Mecp2 specifically
in excitatory neurons caused impaired GABAergic transmission
on cortical pyramidal neurons, which led to seizures and
cortical hyperexcitation (Zhang et al., 2014a). A preclinical
study in female Mecp2 heterozygous mice demonstrated that
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Table 4 | Current clinical trials in RTT individuals.
Agent Results Trial outcome Sponsor Type
Growth Factors
Full length IGF-1 Phase 2 Safety confirmed on-going;
scheduled through Fall 2015
Approved drug in children
with growth failure
Double-blind; placebo
controlled; injection
NNZ-2566 [1–3]IGF-1 analogue Phase 2 Safety confirmed short-term
trial positive
Neuren pharmaceuticals Double-blind; placebo
controlled; oral
BDNF Effectors
Copaxone Phase 2 Improved ambulation Approved drug Open-label; injection
Fingolimod Phase 1 On-going; scheduled through
August 2017
Novartis pharmaceuticals;
Approved drug-adults
Open-label; oral
NMDA Antagonist
Dextromethorphan Phase 2 On-going; scheduled through
June 2015
Approved drug in cough
suppressant
Double-blind;
placebo controlled
Norepinephrine Effector
Desipramine Phase 2 On-going; scheduled through
December 2014
Approved drug in Europe Double-blind;
placebo controlled
Mitochondrial Effector
EPI-743 Phase 2 Safety confirmed Improved
head circumference growth
Edison pharmaceuticals Double-blind; placebo
controlled; oral
increasing ambient GABA levels by inhibiting the GABA reuptake
transporter improved respiratory patterns (Abdala et al., 2010).
Vigabatrin is an antiepileptic drug that irreversibly inhibits GABA
transaminase, inhibits GABA catabolism and thereby increases
GABA levels (Connelly, 1993). The drug is already FDA approved
for use in epilepsy syndromes. Planning for a clinical trial for
RTT is underway. However, retinal toxicity may limit the chronic
use of this medication.
MITOCHONDRIAL FUNCTION
RTT is associated with high levels of systemic oxidative stress
and alteration in mitochondrial morphology, while plasma levels
of oxidative stress biomarkers correlate with disease severity and
progression (De Felice et al., 2012). Based on these observations,
the small molecule EPI-743 was tested in a phase-2 placebo
controlled trial of RTT individuals. Results from this exploratory
trial revealed improvement in head growth but not in other core
features of RTT. The structure of EPI-743 is based on vitamin
E and its proposed mechanisms-of-action includes augmenting
glutathione synthesis and acting at the mitochondrial level to
regulate electron transport.
“READ-THROUGH” COMPOUNDS TO INCREASE MECP2 EXPRESSION
In approximately one-third of RTT individuals, a nonsense
mutation in MECP2 (e.g., R168X, R255X) leads to the premature
termination of transcripton due to a premature STOP codon
(Schanen et al., 2004; Percy et al., 2007). Clinically, these RTT
individuals have a more severe presentation than RTT individuals
with missense MECP2 mutations that result in single amino acid
substitutions. Aminoglycoside antibiotics like gentamycin are so-
called “read-through” compounds because they allow ribosomal
read-through of the premature STOP codon during translation,
yielding a full-length functional protein. Aminoglycoside and
non-aminoglycoside “read-through” compounds have been
tested for therapeutic efficacy in Duchenne muscular dystrophy
and cystic fibrosis (Zingman et al., 2007). Preclinical studies
relevant to RTT have demonstrated that either gentamycin or
geneticin were effective in translating a full-length functional
MeCP2 protein in a lymphocyte cell line derived from an
individual with a R255X nonsense mutation (Popescu et al.,
2010), and in transgenic mice expressing a R168X nonsense
mutation (Brendel et al., 2011). Furthermore, gentamycin
increased dendritic spine density in neurons derived from
induced pluripotent stem cells (iPSC) that were obtained from
a RTT individual with a Q244X nonsense mutation (Marchetto
et al., 2010). However, the renal and auditory toxicity of
gentamycin has limited its progress toward human clinical
trials and prompted the development of new “read-through”
compounds with better safety profiles.
OPEN QUESTIONS AND CHALLENGES
DESIGN AND QUALITY OF PRECLINICAL STUDIES
Although many targeted treatments have shown efficacy across
multiple aspects in ASD animal models, none has thus far
demonstrated the same effectiveness in patients (Katz et al.,
2012; Hagerman et al., 2014). Hurdles to translational success
may include lack of rigorous standards in assessing the effect
of treatment, lack of transparency in reporting preclinical data,
as well as publication bias caused by disregarding negative
results in preclinical studies (Katz et al., 2012). The translational
success stories in fragile X and Rett syndromes indicates that the
effectiveness of targeted treatments in animal models can turn
into clinical efficacy in humans, provided that studies are well
designed, the models are reliable and robust, and that preclinical
outcome measures are relevant to patients (Anagnostou, 2012;
Lipton and Sahin, 2013; Castro et al., 2014; Khwaja et al., 2014).
To achieve more translational success in ASDs, efforts are needed
to improve the quality of preclinical studies in the future. Strict
standards must be implemented for preclinical study designs
and result reporting to ensure that clinical trials are grounded
on reliable preclinical data (Katz et al., 2012; Landis et al.,
2012).
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One of the key issues in preclinical studies is that almost every
study has applied its own animal behavioral experiment battery to
evaluate the effects of genetic or pharmacological manipulations,
making comparison of efficacy among different treatments a
challenge. This situation will be greatly improved if animal
behavioral test batteries for identifying potential therapy could
be standardized. Despite the discrepancies in test batteries from
different laboratories, many of the targeted treatments achieve
predicted effect and rescue at least part of phenotypic features of
the disorders in animal models (Braat and Kooy, 2014; Hagerman
et al., 2014).
CHALLENGES IN CLINICAL TRIALS
Despite progress made in clinical trials, one of the major concerns
for these studies is the lack of appropriate outcome measures for
an objective assessment of patients’ daily performance (Berry-
Kravis et al., 2011; Wijetunge et al., 2013; Berry-Kravis, 2014;
Braat and Kooy, 2014; Jacquemont et al., 2014). As a result,
some improvements following therapeutic intervention might
not be observed without the right measurements. It is helpful
that researchers have been trying to formulate suitable outcome
measures, which could be adjusted accordingly for patients
(Berry-Kravis et al., 2013), such as quantitative event related
potential and expressive language outcome measure which have
been developed for fragile X patients (Hessl et al., 2009).
It is anticipated that these measures will better demonstrate
improvements in language and cognition in individual patients.
In addition, molecular markers, such as ERK, BDNF and MMP9,
can be measured to provide a direct biochemical evidence of
improvement with targeted treatments (Hagerman et al., 2014).
Differential responses to one specific treatment have been
observed in individuals with ASDs. Some subgroups within the
patient cohorts respond to the therapy where others do not, as
evident from clinical trials in fragile X syndrome (Jacquemont
et al., 2011; Berry-Kravis et al., 2012). It is therefore important
and helpful to develop biomarkers for selection of patients that
will benefit from a specific therapy depending on their genotypes
and/or neurobiological phenotypes. For example, if follow-
up studies would confirm that AFQ056 treatment significantly
improves behavior in fully methylated patients, detecting the
methylation status of Fmr1 promoter might help identify a
subgroup of fragile X patients that will respond well to this
treatment (Jacquemont et al., 2011; Braat and Kooy, 2014).
Interference with the molecular pathways disturbed in ASDs
has led to the initiation of clinical trials. The fragile X and Rett
syndromes are the prototypes of neurodevelopmental disorders
for which targeted treatments are becoming realities (Samaco
and Neul, 2011; Chapleau et al., 2013a,b; Braat and Kooy, 2014).
However, it is unlikely that a single compound will be effective
in all individuals with ASDs. Thus, it will be necessary to test
combinations of multiple drugs that each rescue part of clinical
presentations to find a combination of drugs that works more
efficiently than each on its own. Importantly, pharmaceutical
interventions need to be paired with appropriate behavioral and
cognitive training to maximize the efficacy. This represents a
significant step towards more personalized approaches to treating
fragile X, RTT and other ASDs in future, with a better chance of
success (Castro et al., 2013; Wijetunge et al., 2013; Braat and Kooy,
2014; Hagerman et al., 2014).
THE TIMING OF TREATMENT INITIATION
It is generally believed that earlier interventions in developmental
disorders will have better outcomes. Abnormalities occurring
during early development have usually been considered
irreversible in adulthood. However, studies in mouse models
of neurodevelopmental disorders, including fragile X and
Rett syndromes, suggest that many pathophysiological aspects
associated with the disorders can be reversed by genetic or
pharmacological manipulations performed during adulthood
(Castrén et al., 2012). Improvements have also been observed in
adult patients with fragile X syndrome treated with arbaclofen
and AFQ056 (Jacquemont et al., 2011; Henderson et al., 2012).
These findings suggest that the pathophysiology associated with
the loss of FMRP or MeCP2 may not arise from irreversible
developmental brain abnormalities, but result from functional
disturbances of neural circuits that could be corrected in
adulthood, providing a potential rational basis for treatment of
neurodevelopmental disorders in adulthood (Castrén et al., 2012;
Wijetunge et al., 2013; Hagerman et al., 2014). Despite these
exciting advances, translation from animal experimentation to
clinical practice and finding out the right initiation timing for
treating individual patients will be challenging issues in future
investigation (Castrén et al., 2012; Wijetunge et al., 2013).
CONCLUSIONS
The increasing need for effective treatments of fragile X and
Rett syndromes, coupled with the availability of animal models
and iPSC-derived neurons from human individuals with these
disorders (Marchetto et al., 2010; Wang and Doering, 2012),
has promoted translational studies towards identifying potential
therapeutics. New opportunities are now emerging that might
lead to development of novel pharmacotherapies for patients
with fragile X and Rett syndromes. The development of
mechanism-based targeted treatments will require more extensive
multidisciplinary researches (Chapleau et al., 2013a; Berry-Kravis,
2014; Braat and Kooy, 2014; Hagerman et al., 2014). It is the
responsibility of the research community to rigorously validate
disease models, outcome measures and study designs that will
produce robust and reproducible preclinical findings with clear
relevance to human diseases (Katz et al., 2012; Landis et al., 2012).
The rational therapeutics for ASDs requires the knowledge
of an entire spectrum of symptoms that relate to each
specific disorder. The complicated pathophysiology of fragile
X and Rett syndromes should be taken fully into account
in designing preclinical and clinical studies. It should be
recognized that loss of FMRP or MeCP2 will affect a
number of downstream targets which exist not only on
neurons, but on glial cells and other tissues (McCauley
et al., 2011; Cheng et al., 2012; Derecki et al., 2013; Ausió
et al., 2014); that the loss can have direct, as well as
indirect and cumulative effects on development and function
of the central nervous system or other organs, leading to
distinct phenotypic consequences that possibly require different
treatment strategies. Understanding these complexities will be
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essential for selecting relative therapeutics for patients (Chapleau
et al., 2013a,b; Delorme et al., 2013; Berry-Kravis, 2014;
Hagerman et al., 2014). It is inspiring to see that fragile X
and Rett syndromes are becoming role models for how research
in animal models could be translated into patients and how
management of symptoms of the diseases could extend and
improve the quality of life, providing further insights into
understanding and treating ASDs and other neurodevelopmental
diseases.
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